Anti-inflammatories and prostate cancer prevention

Yet again we have the presentation of data suggesting that men who take a regular dose of aspirin (or a similar anti-inflammatory agent) may have a lower overall risk for prostate cancer in general and for high-risk prostate cancer in particular … but please note the word “may” and remember that the daily use of aspirin is not free of risk for side effects — some of which can be significant. … READ MORE …

Dose of radiation, survival, and side effects in intermediate-risk prostate cancer

There were a lot of data presented at the recent annual meeting of the American Society for Radiation Oncology (ASTRO) in San Francisco. Much of the data regarding prostate cancer was of relatively minor significance … but one paper seems to be of considerable importance. … READ MORE …

NCI launches “exceptional responders” initiative

It is well understood that some patients exhibit exceptionally good responses to investigational and to standard forms of treatment for cancer — well beyond the responses exhibited by the majority of patients treated with the same type of investigational or standard treatment. … READ MORE …

What is PI-RADS and why should you care?

PI-RADS is an acronym and it stands for “prostate imaging — reporting and data system” but what it really is is a highly structured method for reporting what can be seen on certain types of prostate-specific magnetic resonance imaging (MRI) scan and how to interpret these data. … READ MORE …

Seven critical prostate cancer controversies

Long-time prostate cancer advocates (and of course all members of the clinical treatment community) are well aware of the controversies that complicate testing for, diagnosing, and managing prostate cancer. However, for men approaching their mid 40s and early 50s and newly diagnosed patients this can come as a major shock. … READ MORE …

Baldness patterns, genetics, and risk for prostate cancer

According to a newly-published study in the Journal of Clinical Oncology, certain types of male baldness are associated with a heightened risk for aggressive forms of prostate cancer (but this finding really needs to be confirmed in other studies). … READ MORE …

D’Amico on the individualization of prostate cancer risk management

In an interesting article in the September 2014 issue of The ASCO Post, Dr. Anthony D’Amico argues in favor of a future in which individualized approaches to risk will replace PSA screening alone as a means of determining who actually needs to be biopsied and (if necessary) receive treatment for clinically significant prostate cancer. … READ MORE …

Follow

Get every new post delivered to your Inbox.

Join 1,152 other followers